The company developed a proprietary ETB platform with differentiated mechanisms compared to antibody-drug conjugates (ADCs). As of January 2025, the company transitioned to winding down operations under new leadership.
Cyborg Score Rationale
The company is no longer operating as of January 2025 and is in the process of winding down business affairs. Historical pipeline progress was limited to early-stage clinical trials before cessation of operations.
Top Insights
Company ceased operations and transitioned to wind-down status in January 2025
Historical focus on engineered toxin body (ETB) platform as alternative to antibody-drug conjugates
Lead program MT-3724 reached Phase 1 trials for non-Hodgkin's lymphoma but did not advance to commercial viability
Raised approximately $41.91M in total venture funding from investors including Excel Venture Management and Santé Ventures
Named Competitors
Ambrx — Antibody-drug conjugate and targeted biotherapeutics platform
Humanigen — Biopharmaceutical company focused on immunotherapy
Recent Developments
(January 2025) Appointed Craig Jalbert as sole executive to wind down business operations
(Prior to 2025) Company ceased active drug development and clinical trial activities
Open the full interactive Molecular Templates, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.